François Ravenelle, PhD, Founder & CEO
François is steering the comeback of cannabinoid receptor-1 (CB1) blockers at Inversago Pharma Inc. Product development professional and entrepreneur with 16 years of industrial R&D experience. Expertise in early-stage programs, from discovery to phase II, but also contributed significantly to one approved NDA.
Christine McCarthy, MD Acting CMO
Christine oversaw clinical development programs at Sanofi, including worldwide responsibility for rimonabant’s large Phase III program. Christine has more than 25 years of experience in large pharma companies.
Jean-Marie Vallet, PhD, MBA Acting CBO
Jean-Marie has over 30 years of experience in the pharma/biotech industry acquired across several functional areas including, Research, Business Development/Licensing, Strategic Planning, Corporate M&A and Finance & Administration.